Get 50% OFF This Monsoon!
SMS Pharmaceuticals
No Data Available
No Stocks
Unlock Smart Score
See Detailed Analysis & Insights
Unlock Insights
See Detailed Analysis & Insights
No Research Report
ROE
Avg ROE (3 Yrs) : NaN%
ROCE
Avg ROCE (3 Yrs) : NaN%
ROA
Avg ROA (3 Yrs) : NaN%
NPM
Avg NPM (3 Yrs) : NaN%
No Data Available
Unlock Management Data
See Detailed Analysis & Insights
SMS Pharmaceuticals Limited is a Public company incorporated in December 14, 1987. The company is engaged in the business of manufacturing of Active Pharma Ingredients and their intermediates. Apart from R &D Center at Gagillapur, Hyderabad, the company is having manufacturing facilities at Bachupally, Hyderabad and also at Kandivalasa in Vijayanagaram Dist. Its business activity is a single primary business segment of 'Bulk Drugs'.
During the year 2015, the company has re-enforced its fundamental strength of FDA compliant facilities by successfully completing the US FDA audits at Kandivalasa and Bachupally facilities.
During the year 2015, the company filed 9 Drug Master Files and total DMFs filed up to 31 March 2015 are 24.
During the year 2014-15, the Company acquired 12,25,900 equity shares of Rs. 10/- each in M/s. VKT Pharma Private Limited. With this the said company has become an associate company. The project of the said associate company is in final stage and at the verge of completion and operations are yet to be commenced. The Company has not having any subsidiaries.
During the year 2015-16, the Company had sub divided the face value of share of Rs 10/- each into face value of Rs 1/- of each with record date of 18th December 2015.
During FY 2015-16, the Board has approved the 'Draft Scheme of Arrangement for Demerger of Semi Regulated Units (Unit - I, IV & V) along with other Assets to transfer the same to SMS Lifesciences India Limited (Resulting Company), with an object to reduce the impact of Semi Regulated Units on Regulated Units, achieving operational efficiencies, site synergies and streamlining its current structure. The Draft Scheme of Arrangement is subject to the Approvals of Stock Exchanges, Securities Board of India Limited, Reserve Bank of India and other regulatory authorities and also Hon'ble High Court of Judicature at Hyderabad for the State of Telangana and Andhra Pradesh.
During FY 2016-17, the Company had made investment in it's associate Company viz. M/s. VKT Pharma Private Limited for its business purpose. During the year under review 2016-17, the Company had acquired 5,11,400 equity shares of face value of Rs 10/- each in the said associate at an average price of Rs 157.21. Further, the Company had also made an investment in 1000 equity shares of Sireen Drugs Private Limited of Rs 10/- each.
SMS Lifesciences India Limited is the wholly owned subsidiary of the Company during the Financial Year 2016-17.
In FY 2017-18, the Scheme of arrangement between SMS Pharmaceuticals Limited (Demerged Company) with SMS Lifesciences India Limited (Resulting Company) and their respective Shareholders and Creditors provides for the demerger of the Semi Regulated Units No. I, IV and V along with premises situated at Industrial Estate, Santhnagar, Hyderabad; Industrial Development Area, Jeedimetla, Hyderabad ; Premises bearing Flat No.417, Nilgiri, Aditya Enclave, Ameerpet, Hyderabad; vacant land admeasuring Ac 19 cents situated at Pharma City, Parawada, Visakhapatnam and Investments relating to Semi Regulated Units (Demerged Undertaking) of SMS Pharmaceuticals Limited, the 'Demerged Company' into SMS Lifesciences India Limited, the 'Resulting Company as specified in the scheme. The scheme was approved by the Hon'ble National Company Law Tribunal, Hyderabad Bench vide its Order No. C.P (CAA) No.7/230/232/HDB/2017 dated 15th May 2017. The effective date of the Scheme is 17th May 2017. SMS Lifesciences India Limited (Resulting Company) in accordance with the approved Scheme of Arrangement has allotted 30,23,287 equity shares of Rs.10/- each to the shareholders of the company by fixing Record Date as on 23rd June, 2017. Pursuant to approved Scheme, the Resulting Company shares will be listed on Stock Exchanges viz., BSE & NSE where the equity shares of SMS Pharmaceuticals Limited are listed.
The Company had made investment in its associate company viz. M/s. VKT Pharma Private Limited for its business purpose. During the year under review 2017-18, the Company had acquired 7,84,100 equity shares of face value of Rs.10/- each in the said associate at an average price of Rs.200.81.
During FY 2018-19, the Company had made investment in it's associate Company viz. M/s. VKT Pharma Private Limited for its business purpose. The Company held 38,50,165 equity shares of Rs 10/- each in VKT Pharma Private Limited as on 31st March 2019 as investments.
SMS Pharmaceuticals share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.
Market capitalization of SMS Pharmaceuticals indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how SMS Pharmaceuticals is valued compared to its competitors.
SMS Pharmaceuticals PE ratio helps investors understand what is the market value of each stock compared to SMS Pharmaceuticals 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.
The PEG ratio of SMS Pharmaceuticals evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.
Return on Equity (ROE) measures how effectively SMS Pharmaceuticals generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.
Return on Capital Employed (ROCE) evaluates the profitability of SMS Pharmaceuticals in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.
Total debt of SMS Pharmaceuticals shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.
The Debt-to-Equity (DE) ratio of SMS Pharmaceuticals compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.
CAGR shows the consistent growth rate of SMS Pharmaceuticals over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.
Technical analysis of SMS Pharmaceuticals helps investors get an insight into when they can enter or exit the stock. Key components of SMS Pharmaceuticals Technical Analysis include:
There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.
There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where SMS Pharmaceuticals shares often struggle to rise above due to selling pressure.
Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect SMS Pharmaceuticals ’s financial health and profitability.
Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.
Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.
The financials of SMS Pharmaceuticals provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.
The profit and loss statement of SMS Pharmaceuticals highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of SMS Pharmaceuticals .
The balance sheet presents a snapshot of SMS Pharmaceuticals ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.
Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.